Extract
This will be our final new year editorial, as in September we will make way for a new editorial team who can continue the evolution of the European Respiratory Journal. Here, we want to look back on some of the highlights of a remarkable year at the ERJ and pay tribute to the pillars of the journal's success, our editors, reviewers and the editorial staff who have worked so hard throughout our 5-year tenure.
Abstract
Editorial review of 2021: look back on some of the highlights of a remarkable year at the European Respiratory Journal https://bit.ly/331l1VN
Footnotes
Conflict of interest: J.D. Chalmers has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Novartis and Insmed; and received consultancy or speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis and Zambon.
Conflict of interest: M. Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic (now Liminal Biosciences) and Pieris; grants from Avalyn; and personal fees from AstraZeneca, Novartis, Cipla, Bluefin Biomedicine, Algernon and Medscape.
- Received January 7, 2022.
- Accepted January 8, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
